# Major Depressive Disorder (MDD) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/major-depressive-disorder-mdd

> 6 upcoming FDA catalysts in major Depressive Disorder (MDD): spn-821 2400 mg (SUPN) on Dec 2026 to Mar 2027 (topline data readout); spn-821 2400 mg (SUPN) on December 2026 (primary completion); alks 7290 dose (ALKS) on January 2028 (primary completion); alks 7290 dose (ALKS) on Jan to Apr 2028 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2026 to Mar 2027 | [Spn-821 2400 mg topline data readout](https://sec-api.dev/pdufa/spn-821) | SUPN | Major Depressive Disorder (MDD) | scheduled | "NCT07226661 (Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226661)) |
| December 2026 | [Spn-821 2400 mg primary completion](https://sec-api.dev/pdufa/spn-821) | SUPN | Major Depressive Disorder (MDD) | scheduled | "NCT07226661 (Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226661)) |
| January 2028 | [Alks 7290 dose primary completion](https://sec-api.dev/pdufa/alks-7290-dose) | ALKS | Major Depressive Disorder (MDD) | scheduled | "NCT07901179 (A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07901179)) |
| Jan to Apr 2028 | [Alks 7290 dose topline data readout](https://sec-api.dev/pdufa/alks-7290-dose) | ALKS | Major Depressive Disorder (MDD) | scheduled | "NCT07901179 (A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07901179)) |
| March 2028 | [BYSANTITM (milsaperidone) primary completion](https://sec-api.dev/pdufa/milsaperidone) | VNDA | Major Depressive Disorder (MDD) | scheduled | "NCT06830044 (Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06830044)) |
| Mar to Jun 2028 | [BYSANTITM (milsaperidone) topline data readout](https://sec-api.dev/pdufa/milsaperidone) | VNDA | Major Depressive Disorder (MDD) | scheduled | "NCT06830044 (Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06830044)) |

## Drugs

- [Spn-821 2400 mg](https://sec-api.dev/pdufa/spn-821) (SUPN)
- [Alks 7290 dose](https://sec-api.dev/pdufa/alks-7290-dose) (ALKS)
- [BYSANTITM (milsaperidone)](https://sec-api.dev/pdufa/milsaperidone) (VNDA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/major-depressive-disorder-mdd.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Major Depressive Disorder (MDD) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/major-depressive-disorder-mdd

```bibtex
@misc{secapidev_indications_major_depressive_disorder_mdd_20261116,
  title        = {Major Depressive Disorder (MDD) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/major-depressive-disorder-mdd}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_major_depressive_disorder_mdd_20261116","title":"Major Depressive Disorder (MDD) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/major-depressive-disorder-mdd","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
